MarketCap
Facebook
X
TelegramAnnual report 2023
added 02-07-2024
Deciphera Pharmaceuticals Gross Profit 2011-2026 | DCPH
Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.
Calculation formula:Importance for business:
Gross Profit = Revenue – Cost of Goods Sold (COGS)
Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
- Raw materials and supplies
- Wages of production personnel
- Depreciation of equipment
- Transportation and warehousing costs (if directly related to production)
- Assessing core business profitability
If gross profit is declining, it may indicate rising production costs or falling sales. - Financial planning
Gross profit is the basis for calculating other key metrics, such as operating and net profit. - Benchmarking against competitors
Gross profit analysis helps compare the efficiency of different companies within the same industry. - Insights into pricing effectiveness
If gross profit is low, the company may be pricing too low or failing to control costs effectively.
- Increase in raw material and supply costs
- Rising production expenses
- Price reductions due to competition
- Decrease in sales volume
- Currency exchange rate fluctuations (for imports/exports)
Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.
Quarterly Gross Profit Deciphera Pharmaceuticals
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | 19.4 M | 15.4 M | 7.08 M | 62 K | - | - | 25 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 25 M | 62 K | 13.4 M |
Gross Profit of other stocks in the Biotechnology industry
| Issuer | Gross Profit | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
180 M | - | 2.43 % | $ 254 M |  Germany |
 |
Coherus BioSciences
CHRS
|
339 M | $ 1.61 | -3.59 % | $ 189 M |  USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.52 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
5.51 M | - | 2.54 % | $ 160 B |  France |
 |
Catalyst Pharmaceuticals
CPRX
|
87.5 M | $ 24.88 | -0.4 % | $ 3.04 B | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
3.94 M | $ 10.02 | -1.16 % | $ 133 M | USA |
 |
Midatech Pharma plc
MTP
|
-428 K | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
12.1 | - | -1.52 % | $ 24.7 M | USA |
 |
Cardiff Oncology
CRDF
|
245 K | $ 1.57 | -0.63 % | $ 105 M | USA |
 |
Acorda Therapeutics
ACOR
|
119 M | - | -24.86 % | $ 820 K | USA |
 |
Alterity Therapeutics Limited
ATHE
|
177 K | $ 3.65 | 1.3 % | $ 8.78 B |  Australia |
 |
Advaxis
ADXS
|
90 K | - | -9.65 % | $ 45.9 M | USA |
 |
DBV Technologies S.A.
DBVT
|
74 K | $ 20.25 | -0.54 % | $ 2.83 B | France |
 |
Adverum Biotechnologies
ADVM
|
2.32 M | - | - | $ 86.2 M | USA |
 |
Aytu BioScience
AYTU
|
45.8 M | $ 2.55 | -4.14 % | $ 16 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
774 M | - | - | - |  Russia |
 |
Dyadic International
DYAI
|
177 K | $ 0.87 | - | $ 31.5 M | USA |
 |
Aeterna Zentaris
AEZS
|
4.73 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
102 K | - | -10.17 % | $ 12.2 K | USA |
 |
Entera Bio Ltd.
ENTX
|
156 K | $ 1.17 | -2.1 % | $ 64 M |  Israel |
 |
Evogene Ltd.
EVGN
|
5.83 M | $ 0.8 | 2.49 % | $ 27.9 M | Israel |
 |
AIkido Pharma
AIKI
|
10 K | - | 1.93 % | $ 17.4 M | USA |
 |
Fate Therapeutics
FATE
|
2.43 M | $ 1.15 | -3.78 % | $ 137 M | USA |
 |
Fennec Pharmaceuticals
FENC
|
20 M | $ 6.2 | -3.43 % | $ 177 M | USA |
 |
Amicus Therapeutics
FOLD
|
561 M | $ 14.46 | 0.03 % | $ 4.46 B | USA |
 |
CureVac N.V.
CVAC
|
-10.6 M | - | - | $ 867 M | Germany |
 |
Alnylam Pharmaceuticals
ALNY
|
195 M | $ 315.4 | -4.52 % | $ 41.3 B | USA |
 |
Gilead Sciences
GILD
|
17.8 B | $ 138.37 | -1.26 % | $ 172 B | USA |
 |
Genmab A/S
GMAB
|
-182 M | $ 27.13 | -2.25 % | $ 17 B |  Danmark |